Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
75%(3 trials)

Phase Distribution

Ph phase_2
3
60%
Ph phase_3
1
20%

Phase Distribution

0

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Other(1)

Detailed Status

Completed4
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (75.0%)
Phase 31 (25.0%)

Trials by Status

unknown120%
completed480%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

NCT01866111
completedphase_3

Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

NCT02535091
completedphase_2

Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures

NCT01397968
unknown

Cenobamate Expanded Access Program (EAP)

NCT04513860
completedphase_2

Efficacy of YKP3089 in Patients With Photosensitive Epilepsy

NCT00616148

Clinical Trials (5)

Showing 5 of 5 trials
NCT01866111Phase 2

A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Completed
NCT02535091Phase 3

Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Completed
NCT01397968Phase 2

Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures

Completed
NCT04513860

Cenobamate Expanded Access Program (EAP)

Unknown
NCT00616148Phase 2

Efficacy of YKP3089 in Patients With Photosensitive Epilepsy

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5